A More Precise Approach to Small Cell Lung Cancer Treatment
In Partnership With
In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.
In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, a medical oncologist and hematologists at Cancer Treatment Centers of America Atlanta, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer (SCLC).
Sharma begins with explaining the prognosis of patients with SCLC, specifically those who present with extensive-stage disease. The 5-year survival rate for these patients is less than 7% and underscores the need for therapies to better treat extensive-stage SCLC (ES-SCLC). For more than 40 years, the standard of care for these patients has been platinum etoposide, and responses are achieved in about 60% of patients. However, the responses are not durable.
Newer immunotherapies have been shown to improve responses, survival, and response duration in patienta with ES-SCLC. For example, the FDA recently granted approval to durvalumab (Imfinzi) for the treatment of patients with ES-SCLC and lurbinectedin for the treatment of patients metastatic SCLC. In addition, drugs like serpulilimab (HLX10), toripalimab, and irinotecan liposome injection (Onivyde) now have the FDA’s attention based on promising clinical trial data.
As the field continues to advance, Sharma explains that more focus should be centered on biomarkers and transcription factors.
“Small cell lung cancer is now being looked at with a molecular characterization, based on whether it's a cold tumor or a hot tumor. We know, in general, a cold tumor may respond to chemotherapy whereas a hot tumor may have better responses to the immunotherapy. So, this characterization of the small cell lung cancer is vital in exploring further treatment strategies for this tumor," Sharma explains.
FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC
December 17th 2024The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum chemotherapy, supported by promising antitumor activity in the phase 2 TROPiCS-03 study.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Does Odronextamab Show Hope in FL and DLBCL Despite Regulatory Hurdles?
November 5th 2024Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.
Read More
